摘要
胸腺素α1是一种针对T淋巴细胞的免疫增强剂,它可以促进T细胞成熟和分化,并可刺激成熟的T细胞、NK细胞产生白细胞介素-2、γ-干扰素、α-干扰素等细胞因子。本文着重对胸腺素α1的生物学功能、作用机制及其在治疗癌症、病毒性肝炎、艾滋病和真菌性疾病方面的临床应用现况进行综述。
参考文献2
-
1Claudio Zavaglia,Remo Severini,Carmine Tinelli,Josè S. Franzone,Aldo Airoldi,Silvana Tempini,Giuseppina Bettale,Gaetano Ideo. A Randomized, Controlled Study of Thymosin-α1 Therapy in Patients with Anti-HBe, HBV-DNA-Positive Chronic Hepatitis B[J] 2000,Digestive Diseases and Sciences(4):690～696
-
2Enrico Garaci,Giovanni Rocchi,Luigi Perroni,Cartesio D’Agostini,Fabrizio Soscia,Sandro Grelli,Antonio Mastino,Cartesio Favalli. Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infectionand interferon-α in human immunodeficiency virus infection[J] 1994,International Journal of Clinical & Laboratory Research(1):23～28
同被引文献41
-
1无.慢性乙型肝炎防治指南[J].实用肝脏病杂志,2006,9(1):8-18. 被引量：825
-
2邹永水 钱肖贞.固相上氨基酸与多肽氨基的测定[J].生物化学与生物物理进展,1978,(4):12-12.
-
3Wong DKH, Cheung AM. O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B[J]. Ann Intern Med, 1993,119:312.
-
4Lin SM, Sheen IS. Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection[J]. Hepatology, 1999,29: 971-975.
-
5Niederau C, Heintges T, Lange S, et al. Long-term followup of HBeAg-positive patients treated with interferon alia for chronic hepatitisB[J]. N EngJ Med, 1996,334:1422-1427.
-
6Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis[J]. Clin Infect Dis,1996,23:131-137.
-
7Hadziyannis S, Bramou T, Makris A, et al. Interferon alfa2b treatment of HBeAg negative/serum HBV DNA positivechronic active hepatitis B[J]. J Hepatol, 1990, 11: S133-S136.
-
8Pastore G, Santantonio T, Milella A, et al. Anti-HBe-positire chronic hepatitis:B with HBV-DNA in the serum: responses to a 6-month course of lymphoblastoid interferon[J].J Hepatol, 1992,20 : 221-225.
-
9Fattovich G,Farci P, Rugge M, et al. A randomized controlled trial of lymphobalastoid interferon-alfa in patients with chronic hepatitis B lacking HBeAg[J]. Hepatology, 1992,15 :584-589.
-
10Lampertico P,Del Ninno E, manzin A, et al. A randomized,controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum[J]. Hepatology,1997,26:1621-1625.
引证文献4
-
1葛秀林.迈普新治疗乙型肝炎后失代偿期肝硬化58例临床分析[J].中国全科医学,2005,8(13):1092-1093.
-
2吕开雪,李华,葛秀林.胸腺素-α1联合干扰素-α治疗181例慢性乙型肝炎的临床观察[J].实用肝脏病杂志,2007,10(6):406-407. 被引量：1
-
3周平.慢性乙型肝炎抗病毒治疗的研究进展[J].空军总医院学报,2004,20(1):31-33. 被引量：1
-
4程虎,韦萍,朱颐申.固相合成胸腺素α_1[J].南京工业大学学报（自然科学版）,2004,26(2):78-80. 被引量：2
二级引证文献4
-
1姚履枫,朱琪,林彩文,张平,胡盈莹,江家骥.早期病毒学应答是评估拉米夫定治疗慢性乙型肝炎疗效的重要指标[J].实用肝脏病杂志,2007,10(1):8-11. 被引量：5
-
2杨丽敏,王玉华,郑美玲,李兰宇,王晋升,彭勋,赵艳茹,邵玫华,孙凤利.胸腺肽α1、苦参素、病毒唑联合治疗丙型肝炎的临床观察[J].热带病与寄生虫学,2008,6(2):87-88. 被引量：3
-
3程磊,唐洋明,殷果,毕开顺,陈晓辉,王铁杰.HPLC法对胸腺法新及其制剂中杂质检查[J].药物分析杂志,2013,33(11):1942-1947. 被引量：8
-
4张洁,程龙,陈霞.顶空气相色谱法测定注射用胸腺法新中5种有机溶剂残留量[J].药物评价研究,2022,45(3):500-503. 被引量：2
-
1唐天序,程合理,韦俊荣.抗菌药物在我院门诊部应用现况的调查与分析[J].安徽医学,1994,15(4):57-59.
-
2寇亚斐.白蛋白的应用现况[J].临床荟萃,1996,11(1):14-14. 被引量：1
-
3史家安,祖冬青.硝苯吡啶的应用现况[J].河南医药信息,1997,5(4):52-54.
-
4金学洙,金锋,曲生明.如何正确使用抗真菌药物[J].中国社区医师,2005,21(6):18-18.
-
5谢辉峰,汪会民.几种抗真菌药物的合理应用及临床评价[J].中华医学写作杂志,2003,10(21):1983-1984.
-
6林榕,楼方定.重组人粒细胞巨噬细胞集落刺激因子临床应用现况及前景[J].中华内科杂志,1994,33(5):342-344. 被引量：6
-
7毛平,吕磊.低分子肝素的临床应用现况[J].国外医学（输血及血液学分册）,1998,21(6):423-426. 被引量：1
-
8徐光伟,马传庚,范鲁雁.儿科抗生素合理应用现况的药物流行病学研究[J].药物流行病学杂志,1999,8(1):26-28. 被引量：3
-
9高绍科,杨占田.蝮蛇抗栓酶皮肤科应用现况[J].药学实践杂志,1997,15(1):7-8.
-
10江正辉,王槐志,陈长宏.拉米夫定在肝移植中应用现况[J].胃肠病学和肝病学杂志,2002,11(3):278-280. 被引量：2
